Eric Leo Eisenstein

Associate Professor in Medicine
Associate Professor in Family Medicine and Community Health
Member in the Duke Clinical Research Institute
Campus mail 2400 Pratt St, Durham, NC 27705
Phone (919) 668-8984
Email address eisen006@mc.duke.edu

Research Interests:

Dr. Eisenstein is a member of the Duke Clinical Research Institute’s Outcomes Research and Assessment Group, with a special interest in understanding the relationships between complex interventions in health care systems and the long-term clinical and economic outcomes of patients. He has served as Principal Investigator for phase II, III, and IV economic and quality of life studies conducted alongside randomized clinical trials in cardiovascular, emergency, pulmonary, and vascular medicine and surgery. He also has conducted health technology evaluations making use of innovative research methods designed to better understand key relationships in observation (non-randomized) patient data. This work has included evaluations of the long-term clinical outcomes of coronary artery disease patients receiving drug-eluting vs. bare metal intracoronary stents, and how the use of clopidogrel changes those relationships. He also has conducted several studies assessing factors contributing to the costs of and evaluating different design considerations for multi-center randomized clinical trials.

In addition to his working in traditional health technology evaluation, Dr. Eisenstein has an interest in evaluating information technologies as interventions in health care systems. In this regard, he has collaborated in the design and conduct of large-scale, randomized clinical trials to evaluate clinical decision support systems. The research objective in these studies has been to develop methods for evaluating health information technologies in practice-based settings using a “tool kit” of inexpensive, yet highly scalable methods that make use of data sets created as a byproduct of normal clinical and administrative operations. The use of these evaluation methods has been demonstrated in four clinical trials that include care process, clinical, economic, and quality of life measurements.

Education and Training

  • D.B.A., Cleveland State University, 1995

Publications

Petersen, John L., John J. Barron, Bradley G. Hammill, Mark J. Cziraky, Kevin J. Anstrom, Peter M. Wahl, Eric L. Eisenstein, et al. “Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database..” Am Heart J 159, no. 3 (March 2010): 462-470.e1. https://doi.org/10.1016/j.ahj.2009.11.031.

PMID
20211310
Full Text

Rajgor, Dimple, Jatin Shah, Sun Kuie Tay, Truls Ostbye, Eric L. Eisenstein, Ranga Krishnan, and Ricardo Pietrobon. “Certificate course in outcomes research..” Med Teach 32, no. 1 (January 2010).

PMID
20104663
Scholars@Duke

Eisenstein, Eric L., William Wijns, Jean Fajadet, Laura Mauri, Rex Edwards, Patricia A. Cowper, David F. Kong, and Kevin J. Anstrom. “Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions)..” Jacc Cardiovasc Interv 2, no. 12 (December 2009): 1178–87. https://doi.org/10.1016/j.jcin.2009.10.011.

PMID
20129543
Full Text

Eisenstein, Eric L., Martin B. Leon, David E. Kandzari, Laura Mauri, Rex Edwards, David F. Kong, Patricia A. Cowper, Kevin J. Anstrom, and Kevin J. ENDEAVOR III Investigators. “Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)..” Jacc Cardiovasc Interv 2, no. 12 (December 2009): 1199–1207. https://doi.org/10.1016/j.jcin.2009.10.009.

PMID
20129546
Full Text

Allen, Larry A., Kevin J. Anstrom, John R. Horton, Linda K. Shaw, Eric L. Eisenstein, and G Michael Felker. “Relationship between anemia and health care costs in heart failure..” J Card Fail 15, no. 10 (December 2009): 843–49. https://doi.org/10.1016/j.cardfail.2009.06.435.

PMID
19944360
Full Text

Leon, Martin B., David E. Kandzari, Eric L. Eisenstein, Kevin J. Anstrom, Laura Mauri, Donald E. Cutlip, Eugenia Nikolsky, et al. “Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)..” Jacc Cardiovasc Interv 2, no. 12 (December 2009): 1208–18. https://doi.org/10.1016/j.jcin.2009.10.008.

PMID
20129547
Full Text

Riles, Eric M., Eric L. Eisenstein, Kevin J. Anstrom, Rex Edwards, Daniel B. Mark, and Judith Hochman. “Cost-effectiveness of an Early Revascularization Strategy for Cardiogenic Shock Based on Long-term Outcomes.” In Circulation, 120:S989–S989. LIPPINCOTT WILLIAMS & WILKINS, 2009.

Scholars@Duke

Eisenstein, Eric L., Jie L. Sun, Kevin J. Anstrom, Elizabeth R. DeLong, Lynda A. Szczech, and Daniel B. Mark. “Assessing the economic attractiveness of coronary artery revascularization in chronic kidney disease patients..” J Med Syst 33, no. 4 (August 2009): 287–97.

PMID
19697695
Scholars@Duke

Douglas, Pamela S., J Matthew Brennan, Kevin J. Anstrom, Art Sedrakyan, Eric L. Eisenstein, Ghazala Haque, David Dai, et al. “Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry..” J Am Coll Cardiol 53, no. 18 (May 5, 2009): 1629–41. https://doi.org/10.1016/j.jacc.2009.03.005.

PMID
19406337
Full Text

Eisenstein, E. L., R. Edwards, P. A. Cowper, D. F. Kong, M. D. Silverstein, D. B. Mark, K. J. Anstrom, and W. Wijns. “ECONOMIC ANALYSIS OF THE ENDEAVOR DRUG-ELUTING STENT VS. THE DRIVER BARE METAL STENT: RESULTS FROM THE ENDEAVOR II TRIAL.” Value in Health 12, no. 3 (May 1, 2009): A152–A152.

Scholars@Duke

Pages